Neoplasms, Head and NeckNCT03178110
Manual Therapy and Use of the Dynasplint for Trismus in Patients With Head and Neck Cancer
A study testing Physical therapy and dynasplint in people with Neoplasms, Head and Neck and Trismus, run by University of Alberta at 2 sites in Canada.
Trial summary
The objectives of this pilot study are to determine the effectiveness of a manual therapy (MT) protocol plus the use of a dynamic jaw opening device on the maximal interincisor distance; on trismus symptoms; on pain-disability outcomes and on the quality of life, anxiety, and depression in subjects with trismus. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neoplasms, Head and Neck, Trismus
- What is being tested?
- Physical therapy and dynasplint
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 2 sitesCanada
- Study dates
- 4 Oct 2018to 15 Jul 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- A diagnosis of head and neck cancer;
- Cancer treatment includes surgery and/ or radiation therapy;
- An oral and an opening of less than 35 mm between the upper and lower incisors (measured with a slide caliper).
Who cannot join
- 17 years or younger;
- Osteoporosis, osteoradionecrosis or active cancer in the region;
- Serious or uncontrolled co-morbid disease that would interfere with testing or treatment;
- Inability to provide informed consent;
- Inability to comply with the assessment and/ or treatment (i.e. unable to attend treatment sessions due to vacation).
Trial locations and contacts
2 sites in 1 country.
Canada2 sites
University of Alberta/ Cross Cancer Institute
Edmonton, Alberta, T6G 2G4
University of Alberta
Edmonton, Alberta, T6G 2G4
About this study
Official title: Effectiveness of Manual Therapy in Combination With a Dynamic Splint (Dynasplint) in the Treatment of Trismus in Patients With Head and Neck Cancer: A Pilot Study
The objectives of this pilot study are to determine the effectiveness of a manual therapy (MT) protocol plus the use of a dynamic jaw opening device on the maximal interincisor distance; on trismus symptoms; on pain-disability outcomes and on the quality of life, anxiety, and depression in subjects with trismus. The proposed pilot study will comprise a single subject design with multiple baseline measures and during treatment phases to determine the effectiveness of the treatment protocol. A minimum sample of 10 subjects will be recruited. The Health Research Ethics Board of Alberta Cancer Committee will approve this study. Participants will receive a MT protocol plus exercises and the use of the DTS device for 8 weeks. The first two weeks of treatment will involve only MT and opening exercises.After this initial 2 weeks, the DTS will be introduced. The participants will receive a session of 30-45 minutes of MT three/two times per week, for 8 weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home.
Analyses: Visual analyses will be performed on participant before, during, and after the intervention. The 2-standard deviation band method will be used to analyze the behavior of each participant on the outcome of interest before, during, and after the treatment. The minimally important difference levels in order to determine clinical relevance will be done. Two effect size indexes will be used: the percentage of non-overlapping data, and the percentage of improvement rate difference.
Read the detailed description
Trismus is a common impairment following treatment for head and neck cancer. The prevalence of trismus ranges from 25% to 46%, and may be the result of a tumour growth, infection, surgery or radiation. Trismus can dramatically affect the quality of life of subjects with cancer in a variety of ways, and may contribute to post treatment depression. Early intervention is key to reduce the chances of complications. Multiple modalities have been used in the treatment of trismus: Physical therapy, hyperbaric oxygen and pentoxifylline, forced mouth opening under general anesthesia, surgical coronoidectomy, botulinum toxin injection and jaw opening devices such as the TheraBite Jaw Motion Rehabilitation and the Dynasplint® Trismus System. Manual therapy (MT) constitutes a wide variety of different techniques which may be categorized into four major groups: manipulation, mobilization, and muscle energy techniques. MT in the form of mobilization associated with exercises has been frequently used to treat temporomandibular disorders (TMD) with promising results. The Dynasplint® Trismus System (DTS) is a jaw opening device used as a self-management strategy for trismus. The DTS provides low-torque, prolonged-duration stretching with the aim of lengthening the affected connective tissue permanently.Positive effects of the use of DTS in patients with trismus to increase mouth opening have been reported. To date, however, the evidence is limited regarding the effectiveness of manual therapy alone or in combination with exercises to treat specifically trismus in patients with head and neck cancer.
The main objectives of this project are: 1) To determine the feasibility and preliminary efficacy of a manual therapy protocol plus the use of a dynamic jaw opening device (DTS) on the maximal interincisor distance (MID) in subjects with trismus.
- To determine the preliminary efficacy the manual therapy protocol plus the use of a dynamic jaw opening device (DTS) on the Gothenburg Trismus Questionnaire (GTQ). 3) To determine the preliminary efficacy of a manual therapy protocol plus the use of a dynamic jaw opening device (DTS) on pain-disability outcomes in subjects with trismus.
- To determine the preliminary efficacy of a manual therapy protocol plus the use of a dynamic jaw opening device (DTS) on the quality of life, anxiety, and depression in subjects with trismus.
This study will be a pilot study and will follow the methodology of a single subject design with multiple baseline measures and during treatment phases to determine the effectiveness of the treatment protocol. The single subject design was chosen because in addition to provide sound research results, clinical significance of the results for a specific group of patients can be derived. Thus, variables that are functionally important for treatment can become evident. The multiple baseline measures will be used because it increases the potential number of comparisons that can be made between and within data series, ultimately strengthening the confidence with which conclusions are made from the data. A minimum sample of 10 subjects who attend the Cross Cancer Institute (CCI) in Edmonton will be recruited for this project. Subjects will be screened for eligibility and if they meet all eligibility criteria, an information letter of the study will be provided and they will be asked to sign a consent form according to the Health Research Ethics Board (HREB) - University of Alberta.
Participants with trismus will receive a manual therapy protocol plus exercises and the use of the DTS device for a duration of 8 weeks twice per week. The first two weeks of treatment, treatment will involve only manual therapy and opening exercises. After this initial 2 weeks, the DTS will be introduced.
Physical Therapy: The participants will receive a session of 30-45 minutes of manual therapy three/two times per week, for eight weeks. Every sessions will be done and will be adapted individually to the needs of each subject.
Home Exercises: All participants will be instructed how to use the Dynasplint® Trismus System (DTS; Dynasplint Systems Inc, Severna Park, Md, USA) at home. Participants' initial introduction to the DTS will include customized fitting (molded patient mouth pieces) and training on donning and doffing of the devices. Verbal and written instructions will be provided throughout the duration of the treatment for safety, general wear and care, and tension setting goals, based on patient tolerance. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, the tension will be increased every 2 weeks until maximum tolerance is reached. Participants will use this device for the duration of the manual therapy and exercise protocol.
Statistical Analysis: To analyse the data, visual analyses will be done. This kind of analyses is really important for single subject design research to determine: whether evidence of a relation between an independent variable and an outcome variable exists and the strength or the magnitude of that relation. The visual analyses will show the behavior of each participant before, during, and after the intervention. The 2-standard deviation band method (2-SD) will be used to analyze the behavior of each participant on the outcome of interest before, during, and after the treatment. Two effect size indexes will be used to analyse the data. The first one will be the percentage of non-overlapping data (PND), that is obtained by counting the number of data points in the intervention phase which do not overlap with the highest or lowest data points in the baseline phase; this number then is divided by the total number of data points in the treatment phase, multiplied by 100. The second effect size index will be the percentage of improvement rate difference (IRD), that considers the difference in successful performance between baseline and intervention phases. The main purpose of using these two effect sizes is to explore the effects of treatment and to describe the phase contrast and design context.
- Conditions
- Neoplasms, Head and Neck, Trismus
- Being tested
- Physical therapy and dynasplint
- Keywords
- physical therapy, cancer rehabilitation
- Medical subject headings
- Head and Neck Neoplasms, Trismus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Physical therapy and dynasplintBehavioural
Participants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased.
| Study group | Role | What they receive |
|---|---|---|
| Physical therapy and dynasplint | Experimental | Participants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 8 weeks. The first two weeks of treatment will include 2 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will remain at two times per week. Receives: Behavioral: Physical therapy and dynasplint |
What is being measured
The primary outcome is the main question the study is designed to answer.
Minimal Inter-incisor Opening
Mouth Opening
Measured: 8 weeks
Secondary outcomes (6)
Gothenburg Trismus Questionnaire
Trismus symptoms
Measured: 8 weeks
Visual Analogue Scale for Pain
10 cm scale for pain
Measured: 8 weeks
Hospital Anxiety and Depression Scale
Brief psychological screening instrument to measure psychological distress
Measured: 8 weeks
Short-Form 36 Health Survey
SF-36 health-related quality of life questionnaire
Measured: 8 weeks
Global Rating Scale
Scale to assess the magnitude of change experienced in pain and jaw function
Measured: 8 weeks
Adherence to protocol
Diary of adherence to treatment
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2017
- Study start4 Oct 2018
- Primary completion31 Dec 2019
- Study completion15 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neoplasms, Head and NeckStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The methodology of a single subject design will be used with multiple baseline and during treatment measures to determine the effectiveness of the treatment protocol.
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- Cross Cancer Institute
- Responsible party
- Sponsor
- Investigators
- Margaret McNeely, PhD, Principal investigator, University of AlbertaSusan Olivo, PhD, Principal investigator, University of Alberta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03178110
- Sponsor's protocol ID
- HREBA-CC-17-0164
- Status last verified
- Jul 2020
- First submitted
- 2 Jun 2017
- Last updated
- 22 Jul 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: No plan in place at this time.
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Manual Therapy in Combination With a Dynamic Splint (Dynasplint) in the Treatment of Trismus in Patients With Head and Neck Cancer: A Pilot Study
- ClinicalTrials.gov ID
- NCT03178110
- Acronym / sponsor ID
- HREBA-CC-17-0164
- Conditions
- Neoplasms, Head and Neck, Trismus
- Keywords
- physical therapy, cancer rehabilitation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Collaborators
- Cross Cancer Institute
- Study start
- 4 Oct 2018 (actual)
- Primary completion
- 31 Dec 2019 (actual)
- Study completion
- 15 Jul 2020 (actual)
- First posted
- 6 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objectives of this pilot study are to determine the effectiveness of a manual therapy (MT) protocol plus the use of a dynamic jaw opening device on the maximal interincisor distance; on trismus symptoms; on pain-disability outcomes and on the quality of life, anxiety, and depression in subjects with trismus. The proposed pilot study will comprise a single subject design with multiple baseline measures and during treatment phases to determine the effectiveness of the treatment protocol. A minimum sample of 10 subjects will be recruited. The Health Research Ethics Board of Alberta Cancer Committee will approve this study. Participants will receive a MT protocol plus exercises and the use of the DTS device for 8 weeks. The first two weeks of treatment will involve only MT and opening exercises.After this initial 2 weeks, the DTS will be introduced. The participants will receive a session of 30-45 minutes of MT three/two times per week, for 8 weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home.
Analyses: Visual analyses will be performed on participant before, during, and after the intervention. The 2-standard deviation band method will be used to analyze the behavior of each participant on the outcome of interest before, during, and after the treatment. The minimally important difference levels in order to determine clinical relevance will be done. Two effect size indexes will be used: the percentage of non-overlapping data, and the percentage of improvement rate difference.
Detailed description
Trismus is a common impairment following treatment for head and neck cancer. The prevalence of trismus ranges from 25% to 46%, and may be the result of a tumour growth, infection, surgery or radiation. Trismus can dramatically affect the quality of life of subjects with cancer in a variety of ways, and may contribute to post treatment depression. Early intervention is key to reduce the chances of complications. Multiple modalities have been used in the treatment of trismus: Physical therapy, hyperbaric oxygen and pentoxifylline, forced mouth opening under general anesthesia, surgical coronoidectomy, botulinum toxin injection and jaw opening devices such as the TheraBite Jaw Motion Rehabilitation and the Dynasplint® Trismus System. Manual therapy (MT) constitutes a wide variety of different techniques which may be categorized into four major groups: manipulation, mobilization, and muscle energy techniques. MT in the form of mobilization associated with exercises has been frequently used to treat temporomandibular disorders (TMD) with promising results. The Dynasplint® Trismus System (DTS) is a jaw opening device used as a self-management strategy for trismus. The DTS provides low-torque, prolonged-duration stretching with the aim of lengthening the affected connective tissue permanently.Positive effects of the use of DTS in patients with trismus to increase mouth opening have been reported. To date, however, the evidence is limited regarding the effectiveness of manual therapy alone or in combination with exercises to treat specifically trismus in patients with head and neck cancer.
The main objectives of this project are: 1) To determine the feasibility and preliminary efficacy of a manual therapy protocol plus the use of a dynamic jaw opening device (DTS) on the maximal interincisor distance (MID) in subjects with trismus.
- To determine the preliminary efficacy the manual therapy protocol plus the use of a dynamic jaw opening device (DTS) on the Gothenburg Trismus Questionnaire (GTQ). 3) To determine the preliminary efficacy of a manual therapy protocol plus the use of a dynamic jaw opening device (DTS) on pain-disability outcomes in subjects with trismus.
- To determine the preliminary efficacy of a manual therapy protocol plus the use of a dynamic jaw opening device (DTS) on the quality of life, anxiety, and depression in subjects with trismus.
This study will be a pilot study and will follow the methodology of a single subject design with multiple baseline measures and during treatment phases to determine the effectiveness of the treatment protocol. The single subject design was chosen because in addition to provide sound research results, clinical significance of the results for a specific group of patients can be derived. Thus, variables that are functionally important for treatment can become evident. The multiple baseline measures will be used because it increases the potential number of comparisons that can be made between and within data series, ultimately strengthening the confidence with which conclusions are made from the data. A minimum sample of 10 subjects who attend the Cross Cancer Institute (CCI) in Edmonton will be recruited for this project. Subjects will be screened for eligibility and if they meet all eligibility criteria, an information letter of the study will be provided and they will be asked to sign a consent form according to the Health Research Ethics Board (HREB) - University of Alberta.
Participants with trismus will receive a manual therapy protocol plus exercises and the use of the DTS device for a duration of 8 weeks twice per week. The first two weeks of treatment, treatment will involve only manual therapy and opening exercises. After this initial 2 weeks, the DTS will be introduced.
Physical Therapy: The participants will receive a session of 30-45 minutes of manual therapy three/two times per week, for eight weeks. Every sessions will be done and will be adapted individually to the needs of each subject.
Home Exercises: All participants will be instructed how to use the Dynasplint® Trismus System (DTS; Dynasplint Systems Inc, Severna Park, Md, USA) at home. Participants' initial introduction to the DTS will include customized fitting (molded patient mouth pieces) and training on donning and doffing of the devices. Verbal and written instructions will be provided throughout the duration of the treatment for safety, general wear and care, and tension setting goals, based on patient tolerance. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, the tension will be increased every 2 weeks until maximum tolerance is reached. Participants will use this device for the duration of the manual therapy and exercise protocol.
Statistical Analysis: To analyse the data, visual analyses will be done. This kind of analyses is really important for single subject design research to determine: whether evidence of a relation between an independent variable and an outcome variable exists and the strength or the magnitude of that relation. The visual analyses will show the behavior of each participant before, during, and after the intervention. The 2-standard deviation band method (2-SD) will be used to analyze the behavior of each participant on the outcome of interest before, during, and after the treatment. Two effect size indexes will be used to analyse the data. The first one will be the percentage of non-overlapping data (PND), that is obtained by counting the number of data points in the intervention phase which do not overlap with the highest or lowest data points in the baseline phase; this number then is divided by the total number of data points in the treatment phase, multiplied by 100. The second effect size index will be the percentage of improvement rate difference (IRD), that considers the difference in successful performance between baseline and intervention phases. The main purpose of using these two effect sizes is to explore the effects of treatment and to describe the phase contrast and design context.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The methodology of a single subject design will be used with multiple baseline and during treatment measures to determine the effectiveness of the treatment protocol.
| Arm | Type | Receives |
|---|---|---|
| Physical therapy and dynasplint | Experimental | Behavioral: Physical therapy and dynasplintParticipants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 8 weeks. The first two weeks of treatment will include 2 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will remain at two times per week. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- A diagnosis of head and neck cancer;
- Cancer treatment includes surgery and/ or radiation therapy;
- An oral and an opening of less than 35 mm between the upper and lower incisors (measured with a slide caliper).
Key exclusion criteria (5 listed)
- 17 years or younger;
- Osteoporosis, osteoradionecrosis or active cancer in the region;
- Serious or uncontrolled co-morbid disease that would interfere with testing or treatment;
- Inability to provide informed consent;
- Inability to comply with the assessment and/ or treatment (i.e. unable to attend treatment sessions due to vacation).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Physical therapy and dynasplintParticipants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased. | Behavioural | Physical therapy and dynasplint |
Primary outcome
Minimal Inter-incisor Opening
Time frame: 8 weeks
Mouth Opening
6 secondary outcomes
Gothenburg Trismus Questionnaire
Time frame: 8 weeks
Visual Analogue Scale for Pain
Time frame: 8 weeks
Hospital Anxiety and Depression Scale
Time frame: 8 weeks
Short-Form 36 Health Survey
Time frame: 8 weeks
Global Rating Scale
Time frame: 8 weeks
Adherence to protocol
Time frame: 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2020.
- Individual participant dataSharing planned: Undecided. No plan in place at this time.
Related trials for Neoplasms, Head and Neck
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Margaret McNeely, PhD principal investigator
University of Alberta
Susan Olivo, PhD principal investigator
University of Alberta
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Physical therapy and dynasplint in people with Neoplasms, Head and Neck and Trismus, run by University of Alberta at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Minimal Inter-incisor Opening (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2020.